QNRX - Quoin Pharmaceuticals, Ltd.

Insider Purchase by Langer Dennis (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

4 months ago, Langer Dennis, serving as Dir at Quoin Pharmaceuticals, Ltd. (QNRX), purchased 15,152 shares at $8.49 per share, for a total transaction value of $128,640.00. Following this transaction, Langer Dennis now holds 15,153 shares of QNRX.

The trade was executed on Tuesday, October 14, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, October 15, 2025, 1 day after the trade was made.

Quoin Pharmaceuticals, Ltd. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Langer Dennis

Dir

Dennis H. Langer, M.D., J.D., born September 8, 1951, in New York City, is an independent director at Quoin Pharmaceuticals Ltd. (QNRX), serving since 2019 for Quoin Inc. and October 28, 2021, for Quoin Ltd.[[1]](https://fintool.com/app/research/companies/QNRX/people/dennis-langer)[[4]](https://quoinpharma.com/team/dennis-h-langer-md-jd/) He chairs the Compensation Committee, briefly acted as Interim Chairman from October 28 to December 4, 2024, and demonstrates strong board engagement with over 75% attendance in FY2024 meetings.[[1]](https://fintool.com/app/research/companies/QNRX/people/dennis-langer) Langer holds an M.D. from Georgetown University School of Medicine (1975), J.D. cum laude from Harvard Law School (1983), and B.A. in Biology from Columbia University.[[1]](https://fintool.com/app/research/companies/QNRX/people/dennis-langer)[[2]](https://www.doximity.com/pub/dennis-langer-md)[[6]](https://whoswhoindustryleaders.com/2019/09/06/dennis-langer/) Langer's career highlights include President, North America, at Dr. Reddy’s Laboratories (2004–2005), SVP roles in R&D, portfolio management, and alliance management at GlaxoSmithKline (1994–2004), and President & CEO of Neose Technologies (1991–1994), alongside earlier positions at Eli Lilly, Abbott, and Searle.[[1]](https://fintool.com/app/research/companies/QNRX/people/dennis-langer)[[3]](https://braeburnrx.com/about-us/board-of-directors/dennis-h-langer) A board veteran, he has directed public companies like Myriad Genetics (2004–2022), Dicerna Pharmaceuticals (2007–2019), and Brooklyn ImmunoTherapeutics (2021–2022), and currently serves on boards including Braeburn, Inc., Whitehead Institute for Biomedical Research (since 2020), and Harvard Law School Dean’s Advisory Board (since 2010).[[1]](https://fintool.com/app/research/companies/QNRX/people/dennis-langer)[[2]](https://www.doximity.com/pub/dennis-langer-md)[[3]](https://braeburnrx.com/about-us/board-of-directors/dennis-h-langer) His dual medical-legal expertise supports biopharma oversight, with a background in psychiatry residency at Yale-New Haven and fellowships in child & adolescent psychiatry.[[2]](https://www.doximity.com/pub/dennis-langer-md)

View full insider profile →

Trade Price

$8.49

Quantity

15,152

Total Value

$128,640.00

Shares Owned

15,153

Trade Date

Tuesday, October 14, 2025

131 days ago

SEC Filing Date

Wednesday, October 15, 2025

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Quoin Pharmaceuticals, Ltd.

Company Overview

No company information available
View news mentioning QNRX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/778620

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime